Skip to main content

Watts Ryan J.'s Form 4 filing

Denali Therapeutics Inc. (DNLI) · filed Jul 11, 2025

Accession no.
0001714899-25-000149
Filed
Jul 11, 2025
Trade date
Jul 9, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $7.43M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Watts Ryan J.CIK 0001724310Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 9, 2025Common StockMOption exerciseAcquired+455,282$0.68+$309,591.76708,353Direct
Jul 9, 2025Common StockMOption exerciseAcquired+40,000$5.28+$211,200748,353Direct
Jul 9, 2025Common StockSSaleDisposed−495,282$15.00−$7,429,230253,071Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 9, 2025Common StockMOption exerciseDisposed−455,282$0.00$0622,809Direct
Jul 9, 2025Common StockMOption exerciseDisposed−40,000$0.00$020,369Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)